Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Molecular Medicine Reports|February 7, 2012
The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's diseaseErik Portelius, Juan Fortea, Jose Luis Molinuevo, et al.
Dementia and Geriatric Cognitive Disorders|October 16, 2007
Longitudinal study of amnesic patients at high risk for Alzheimer's disease: clinical, neuropsychological and magnetic resonance spectroscopy featuresLorena Rami, Beatriz Gómez-Anson, Raquel Sanchez-Valle, et al.
Annals of Neurology|August 3, 2020
Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and NeurodegenerationJon Landa, Carles Gaig, Jesús Plagumà, et al.
Neuroimage. Clinical|March 27, 2019
Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's diseaseStavros Skouras, Carles Falcon, Alan Tucholka, et al.
Frontiers in Psychiatry|February 23, 2026
Evaluating contributions of neuropsychological, psychiatric, and inflammatory processes to the expression of cognitive symptoms in post-acute COVID-19 syndromeLuke S Watson, Youssef Toubouti, Sarah M Gray, et al.
Alzheimer'S Research & Therapy|April 6, 2024
Utility of visual rating scales in primary progressive aphasiaNeus Falgàs, Luca Sacchi, Tiziana Carandini, et al.
Current Research in Neurobiology|July 3, 2023
Thalamic nuclei changes in early and late onset Alzheimer's diseaseGonzalo Forno, Manojkumar Saranathan, Jose Contador, et al.
Annals of Neurology|June 25, 2013
Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer diseasePetar Podlesniy, Joana Figueiro-Silva, Albert Llado, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|August 7, 2012
Atypical neuropathological sCJD-MM phenotype with abundant white matter Kuru-type plaques sparing the cerebellar cortexEllen Gelpi, Josep Ma Soler Insa, Piero Parchi, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b studyRik Vandenberghe, Marie-Emmanuelle Riviere, Angelika Caputo, et al.
Pageof 14